Fig 1: Selumetinib inhibits IL-1ß-induced activation of necroptosis-related, MAPK and NF-?B signalling pathways and attenuates inflammatory responses. (A,B) Western blot revealed the effect of Selumteinib on necroptosis-related proteins, including p-RIP1/RIP1, p-RIP3/RIP3, p-MLKL/MLKL. (C–F) Selumetinib affected the NF-?B pathway-related proteins, including p-I?Ba, I?Ba, p-p65 and p65. (G–J) The effects of selumetinib on MAPK signalling pathway proteins, including p-ERK/ERK, p-JNK/JNK and p-p38/p38. Data are presented as mean ± S.D. n = 3. Significant differences between groups are indicated as ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.